FDA's Speedy Apple Watch De Novos Raise Questions For Industry
Executive Summary
The recent US FDA de novo approvals for heart-rhythm analysis software on Apple's latest Apple Watch, which took about 30 days from submission to a decision that aligned with Apple's high-profile launch event, raised eyebrows in the medtech industry. Some in industry are concerned that the tech giant received preferential treatment over smaller companies, setting a bad precedent. But some say it could be a positive sign for the digital health industry at large.
You may also be interested in...
FDA Codifies Down-Classification For Devices Such As The Apple Watch ECG App
The agency has codified its over-the-counter ECG software class II classification, which means sponsors can continue to benefit from filing for such apps through the less burdensome 510(k) pathway.
Fitbit Has OTC Electrocardiogram App To Rival Apple, Samsung With Clearance In US, EU
Fitbit will launch its new Fitbit Sense smartwatch with ECG app in Europe, US, Hong Kong and India in October.
Fitbit Receives FDA Clearance, CE Mark For ECG App To Rival Apple
Fitbit will launch its new Fitbit Sense smartwatch with ECG app in Europe, US, Hong Kong and India in October.